Strategic merger and acquisition amongst the companies to expand the market for anti-body coupled T receptor therapy.
Unum Therapeutics is currently the only company that is working actively in anti-body coupled T receptor therapy. It has several product in its pipeline, and they vary based on the technology used for expression of receptor in patients T cell such as mRNA or viral vector. There is also combination of different monoclonal antibodies to be used for coupling such as rituximab, and trastuzumab. In phase one clinical trial, rituximab coupled t receptor therapy found to produce desired therapeutic effects. Seattle Genetics, Inc. and Unum Therapeutics, Inc. in 2015 entered into a strategic collaboration and license agreement to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer. This collaboration would enable study of different combination of the tumor-specific monoclonal antibodies with T receptor and cater to patient specific treatment needs.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients